A pharamacological rationale for neoadjuvant chemotherapy with adriamycin in locally advanced breast cancer

G. Gasparini, G. Toffoli, G. Berlanda, C. Rossi

Research output: Contribution to journalArticle

Abstract

Some locally advanced neoplastic diseases (i.e. head and neck cancer, breast cancer and osteogenic sarcoma), benefit from neoadjuvant chemotherapy with a resultant enhanced operability and a longer disease-free survival. The pharmacological study of the tissue distribution of adriamycin in patients affected by locally advanced breast cancer has shown a preferable tropism of the drug toward the primary tumor and axillary lymph nodes. Median concentrations of the drug in the tumor were: 9.68 μg/gr at 30 minutes, 8.71 μg/gr at 24 hours and 6.44 μg/gr at 48 hours. Median concentration in lymph nodes at 48 hours was 10.80 in normal and 16.62 in metastatic. Lower concentrations were found at 48 hours in the mammary gland (mean 1.72 μg/gr), skin (mean 0.59 μg/gr) and in muscle tissue (mean 1.83 μg/gr in normal and 2.41 μg/gr in metastatic). As regards acute toxicity, we observed that grade II-III leukopenia was associated with longer plasmatic T( 1/2 )β (3 out of 6 patients) and that grade II mucositis was related to high plasma AUC values (3 out of 6 patients). Nausea and vomiting and alopecia seem to be unrelated to plasma pharmacokinetics parameters. After a median follow-up of 36 months it is suggestive that high drug concentrations in carcinoma and in metastatic lymph nodes may be predictive of longer disease-free survival and overall survival. These data give a further rationale for the use of polychemotherapies containing adriamycin in the pre-operative treatment of locally advanced breast cancer.

Original languageEnglish
Pages (from-to)193-196
Number of pages4
JournalAnticancer Research
Volume10
Issue number1
Publication statusPublished - 1990

Fingerprint

Doxorubicin
Breast Neoplasms
Drug Therapy
Lymph Nodes
Disease-Free Survival
Pharmaceutical Preparations
Mucositis
Tropism
Alopecia
Leukopenia
Tissue Distribution
Osteosarcoma
Human Mammary Glands
Head and Neck Neoplasms
Combination Drug Therapy
Nausea
Area Under Curve
Vomiting
Neoplasms
Pharmacokinetics

Keywords

  • breast cancer
  • neoadjuvant chemotherapy
  • pharmacokinetics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A pharamacological rationale for neoadjuvant chemotherapy with adriamycin in locally advanced breast cancer. / Gasparini, G.; Toffoli, G.; Berlanda, G.; Rossi, C.

In: Anticancer Research, Vol. 10, No. 1, 1990, p. 193-196.

Research output: Contribution to journalArticle

@article{dbf9070c717348ca9a04180306e5bf24,
title = "A pharamacological rationale for neoadjuvant chemotherapy with adriamycin in locally advanced breast cancer",
abstract = "Some locally advanced neoplastic diseases (i.e. head and neck cancer, breast cancer and osteogenic sarcoma), benefit from neoadjuvant chemotherapy with a resultant enhanced operability and a longer disease-free survival. The pharmacological study of the tissue distribution of adriamycin in patients affected by locally advanced breast cancer has shown a preferable tropism of the drug toward the primary tumor and axillary lymph nodes. Median concentrations of the drug in the tumor were: 9.68 μg/gr at 30 minutes, 8.71 μg/gr at 24 hours and 6.44 μg/gr at 48 hours. Median concentration in lymph nodes at 48 hours was 10.80 in normal and 16.62 in metastatic. Lower concentrations were found at 48 hours in the mammary gland (mean 1.72 μg/gr), skin (mean 0.59 μg/gr) and in muscle tissue (mean 1.83 μg/gr in normal and 2.41 μg/gr in metastatic). As regards acute toxicity, we observed that grade II-III leukopenia was associated with longer plasmatic T( 1/2 )β (3 out of 6 patients) and that grade II mucositis was related to high plasma AUC values (3 out of 6 patients). Nausea and vomiting and alopecia seem to be unrelated to plasma pharmacokinetics parameters. After a median follow-up of 36 months it is suggestive that high drug concentrations in carcinoma and in metastatic lymph nodes may be predictive of longer disease-free survival and overall survival. These data give a further rationale for the use of polychemotherapies containing adriamycin in the pre-operative treatment of locally advanced breast cancer.",
keywords = "breast cancer, neoadjuvant chemotherapy, pharmacokinetics",
author = "G. Gasparini and G. Toffoli and G. Berlanda and C. Rossi",
year = "1990",
language = "English",
volume = "10",
pages = "193--196",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "1",

}

TY - JOUR

T1 - A pharamacological rationale for neoadjuvant chemotherapy with adriamycin in locally advanced breast cancer

AU - Gasparini, G.

AU - Toffoli, G.

AU - Berlanda, G.

AU - Rossi, C.

PY - 1990

Y1 - 1990

N2 - Some locally advanced neoplastic diseases (i.e. head and neck cancer, breast cancer and osteogenic sarcoma), benefit from neoadjuvant chemotherapy with a resultant enhanced operability and a longer disease-free survival. The pharmacological study of the tissue distribution of adriamycin in patients affected by locally advanced breast cancer has shown a preferable tropism of the drug toward the primary tumor and axillary lymph nodes. Median concentrations of the drug in the tumor were: 9.68 μg/gr at 30 minutes, 8.71 μg/gr at 24 hours and 6.44 μg/gr at 48 hours. Median concentration in lymph nodes at 48 hours was 10.80 in normal and 16.62 in metastatic. Lower concentrations were found at 48 hours in the mammary gland (mean 1.72 μg/gr), skin (mean 0.59 μg/gr) and in muscle tissue (mean 1.83 μg/gr in normal and 2.41 μg/gr in metastatic). As regards acute toxicity, we observed that grade II-III leukopenia was associated with longer plasmatic T( 1/2 )β (3 out of 6 patients) and that grade II mucositis was related to high plasma AUC values (3 out of 6 patients). Nausea and vomiting and alopecia seem to be unrelated to plasma pharmacokinetics parameters. After a median follow-up of 36 months it is suggestive that high drug concentrations in carcinoma and in metastatic lymph nodes may be predictive of longer disease-free survival and overall survival. These data give a further rationale for the use of polychemotherapies containing adriamycin in the pre-operative treatment of locally advanced breast cancer.

AB - Some locally advanced neoplastic diseases (i.e. head and neck cancer, breast cancer and osteogenic sarcoma), benefit from neoadjuvant chemotherapy with a resultant enhanced operability and a longer disease-free survival. The pharmacological study of the tissue distribution of adriamycin in patients affected by locally advanced breast cancer has shown a preferable tropism of the drug toward the primary tumor and axillary lymph nodes. Median concentrations of the drug in the tumor were: 9.68 μg/gr at 30 minutes, 8.71 μg/gr at 24 hours and 6.44 μg/gr at 48 hours. Median concentration in lymph nodes at 48 hours was 10.80 in normal and 16.62 in metastatic. Lower concentrations were found at 48 hours in the mammary gland (mean 1.72 μg/gr), skin (mean 0.59 μg/gr) and in muscle tissue (mean 1.83 μg/gr in normal and 2.41 μg/gr in metastatic). As regards acute toxicity, we observed that grade II-III leukopenia was associated with longer plasmatic T( 1/2 )β (3 out of 6 patients) and that grade II mucositis was related to high plasma AUC values (3 out of 6 patients). Nausea and vomiting and alopecia seem to be unrelated to plasma pharmacokinetics parameters. After a median follow-up of 36 months it is suggestive that high drug concentrations in carcinoma and in metastatic lymph nodes may be predictive of longer disease-free survival and overall survival. These data give a further rationale for the use of polychemotherapies containing adriamycin in the pre-operative treatment of locally advanced breast cancer.

KW - breast cancer

KW - neoadjuvant chemotherapy

KW - pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=0025194645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025194645&partnerID=8YFLogxK

M3 - Article

C2 - 2334126

AN - SCOPUS:0025194645

VL - 10

SP - 193

EP - 196

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 1

ER -